4 completed, 2 unknown, 1 active not recruiting, 1 withdrawn. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 4, Unknown 2, Active not recruiting 1, Withdrawn 1 |
Follow pasireotide: new trials by email Literature Review of pasireotide trials Research Report on pasireotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery Pasireotide 0.3 MG/ML, Meal tolerance test (MTT) - Hypoglycemia, Reactive | Phase 4 | Unknown | Zealand University Hospital | 5 | 2018-06-01 | 2018-07-05 |
| HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications Hydrocortisone, Pasireotide - Pancreatic Fistula, Pancreatic Neoplasms | Phase 4 | Active not recruiting | Helsinki University Central Hospital | 126 | 2016-05-01 | 2020-08-24 |
| Pasireotide Treatment for Neuroendocrine Tumor Pasireotide, Diazoxide - Gastro-enteropancreatic Neuroendocrine Tumor | Phase 4 | Withdrawn | University of Maryland, Baltimore | 2016-04-01 | 2022-03-04 | |
| Treatment of Hypoglycemia Following Gastric Bypass Surgery Glucobay (acarbose), Januvia (sitagliptin), Verapamil HEXAL (verapamil) - Hypoglycemia, Obesity | Phase 4 | Completed | Zealand University Hospital | 11 | 2015-10-01 | 2018-03-07 |
| Pasireotide LAR and Pegvisomant Study in Acromegaly Pasireotide LAR 60 mg, Pegvisomant - Acromegaly | Phase 4 | Unknown | Erasmus Medical Center | 60 | 2015-08-01 | 2016-08-03 |
| Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Pasireotide s.c., Sitagliptin, Liraglutide - Cushing's Disease, Acromegaly | Phase 4 | Completed | Novartis Pharmaceuticals | 249 | 2014-05-23 | 2019-05-29 |
| Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Pasireotide, Cabergoline, Pasireotide LAR - Cushing's Disease, Acromegaly | Phase 4 | Completed | RECORDATI GROUP | 337 | 2013-06-10 | 2024-10-01 |
| Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Pasireotide 0.6 MG/ML - Cushing Disease | Phase 4 | Completed | University of Palermo | 24 | 2013-05-01 | 2017-10-27 |
Acromegaly (3) · Hypoglycemia (3) · Pituitary ACTH Hypersecretion (3) · Dumping Syndrome (1) · Gastro-enteropancreatic neuroendocrine tumor (1) · Hyperglycemia (1) · Hyperinsulinism (1) · Melanoma (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Obesity (1) · Pancreatic Fistula (1) · Pancreatic Neoplasms (1) · Pituitary Neoplasms (1) · Prostatic Neoplasms (1)
Zealand University Hospital (2) · Erasmus Medical Center (1) · Helsinki University Central Hospital (1) · Novartis Pharmaceuticals (1) · RECORDATI GROUP (1) · University of Maryland, Baltimore (1) · University of Palermo (1)
Belgium (2) · Brazil (2) · Denmark (2) · Germany (2) · India (2) · Netherlands (2) · Peru (2) · Poland (2) · Russia (2) · Thailand (2) · Turkey (Türkiye) (2) · United States (2) · Argentina (1) · Bulgaria (1) · Canada (1)
Caroline C Gormsen, M.D. (1) · Kashif M Munir, MD (1) · Sebastian Neggers, MD PhD (1)
PMID 27405306, PMID 29155991, PMID 31907828, PMID 32022887, PMID 34275099
2014 (1)